AI-Powered Drug Marketer Medvi Responds After Allegations About Fake Doctors and Patients

Published: Thursday, April 9, 2026 at 10:07 pm

Medvi's Response to Allegations of Deceptive Marketing Practices

Medvi, an AI-powered drug marketing company, has responded to criticism regarding its marketing practices following a recent profile in the *New York Times*. The company, which focuses on marketing telehealth services for GLP-1 agonists and other compounded drugs, has faced scrutiny over allegations of using deceptive tactics.

The core of the controversy revolves around the company's marketing materials. Critics have pointed to the use of AI-generated images of patients, the implication of media coverage that didn't exist, and the inclusion of medical practitioners who denied any affiliation with Medvi. These issues were largely omitted or downplayed in the *New York Times* profile.

The Food and Drug Administration (FDA) issued a warning to Medvi LLC in February 2026, citing violations on the website Medvi.io. The FDA alleged the site misled consumers by featuring images of Medvi-branded products and suggesting certain drug compounds were FDA-approved when they were not. Medvi's response attempts to distance itself from the FDA warning, claiming it was directed at an affiliate marketing agency. The company insists it has never received a letter from the FDA.

Medvi's statement also addresses the use of "fake doctors" in its social media marketing. The company claims it only recently became aware of these advertisements and has updated its marketing practices to prohibit such promotions. However, the statement fails to address the continued use of AI-generated before-and-after patient pictures.

The company's founder, Matthew Gallagher, stated that building a company of Medvi's size involves "many learning moments" and that he has "course-corrected immediately and appropriately." He also emphasized a commitment to transparency.

BNN's Perspective:

The situation surrounding Medvi raises serious questions about the ethical implications of AI in marketing, particularly in the healthcare sector. While the company claims to be addressing the issues, the lack of clear answers and the continued use of potentially misleading practices are concerning. Consumers should exercise caution and conduct thorough research before engaging with companies like Medvi.

Keywords: Medvi, AI, drug marketing, FDA, deceptive practices, fake doctors, patient images, GLP-1 agonists, telehealth, marketing ethics, Matthew Gallagher, transparency, compounded drugs, FDA warning

Full Story